Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors

Molecular Therapy

Volumn 18, Issue 6, 2010, Pages 1067-1075

  Bexell, Daniel ^a,b   Scheding, Stefan ^a,c   Bengzon, Johan ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; BETA INTERFERON; CONDITIONALLY REPLICATING ADENOVIRUS; CYTOKINE; CYTOSINE DEAMINASE; FLUCYTOSINE; FRACTALKINE; GANCICLOVIR; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 7; ONCOLYTIC ADENOVIRUS; ONCOLYTIC VIRUS; THYMIDINE KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VIRUS VECTOR; PRODRUG;

BRAIN TUMOR; CANCER GENE THERAPY; CANCER INVASION; CELL BASED GENE THERAPY; CELL HOMING; CELL MIGRATION; CELLULAR DISTRIBUTION; COLON CARCINOMA; DRUG MECHANISM; DRUG METABOLISM; GENE DELIVERY SYSTEM; GENE VECTOR; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; LUNG METASTASIS; MALIGNANT TRANSFORMATION; MELANOMA; MESENCHYMAL STEM CELL; MULTIPOTENT STEM CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PANCREAS CANCER; PERICYTE; PROSTATE TUMOR; REVIEW; TRANSGENE; TUMOR GROWTH; ANIMAL; BRAIN NEOPLASMS; CELL MOTION; CYTOLOGY; GENE THERAPY; MESENCHYMAL STROMA CELL; METABOLISM; MOUSE; PATHOLOGY; RAT; STROMA CELL;

ANIMALS; BRAIN NEOPLASMS; CELL MOVEMENT; CYTOKINES; GENE THERAPY; GENETIC VECTORS; HUMANS; MESENCHYMAL STEM CELLS; MICE; ONCOLYTIC VIROTHERAPY; PRODRUGS; RATS; STROMAL CELLS; GENETIC THERAPY; MESENCHYMAL STROMAL CELLS;

EID: 77953133974     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.58     Document Type: Review

References (110)

1. Stupp, R, Mason, WP, van den Bent, MJ, Weller, M, Fisher, B, Taphoorn, MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
2. Calabrese, C, Poppleton, H, Kocak, M, Hogg, TL, Fuller, C, Hamner, B et al. (2007). A perivascular niche for brain tumor stem cells. Cancer Cell 11: 69-82.
3. Singh, SK, Hawkins, C, Clarke, ID, Squire, JA, Bayani, J, Hide, T et al. (2004). Identifcation of human brain tumour initiating cells. Nature 432: 396-401.
4. Stiles, CD and Rowitch, DH (2008). Glioma stem cells: a midterm exam. Neuron 58: 832-846.
5. Caplan, AI (2009). Why are MSCs therapeutic? New data: new insight. J Pathol 217: 318-324.
6. Crisan, M, Yap, S, Casteilla, L, Chen, CW, Corselli, M, Park, TS et al. (2008). A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3: 301-313.
7. Dominici, M, Le Blanc, K, Mueller, I, Slaper-Cortenbach, I, Marini, F, Krause, D et al. (2006). Minimal criteria for defning multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317.
8. Baksh, D, Song, L and Tuan, RS (2004). Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med 8: 301-316.
9. Friedenstein, AJ, Chailakhyan, RK, Latsinik, N V, Panasyuk, AF and Keiliss-Borok, IV (1974). Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 17: 331-340.
10. Prockop, DJ (2009). Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther 17: 939-946.
11. Jones, BJ and McTaggart, SJ (2008). Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp Hematol 36: 733-741.
12. Le Blanc, K, Frassoni, F, Ball, L, Locatelli, F, Roelofs, H, Lewis, I et al.; Developmental Committee of the European Group for Blood and Marrow Transplantation. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371: 1579-1586.
13. Au, P, Tam, J, Fukumura, D and Jain, RK (2008). Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood 111: 4551-4558.
14. Sacchetti, B, Funari, A, Michienzi, S, Di Cesare, S, Piersanti, S, Saggio, I et al. (2007). Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 131: 324-336.
15. Pulkkanen, KJ and Yla-Herttuala, S (2005). Gene therapy for malignant glioma: current clinical status. Mol Ther 12: 585-598.
16. Aboody, KS, Brown, A, Rainov, NG, Bower, KA, Liu, S, Yang, W et al. (2000). Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 97: 12846-12851.
17. Benedetti, S, Pirola, B, Pollo, B, Magrassi, L, Bruzzone, MG, Rigamonti, D et al. (2000). Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 6: 447-450.
18. Ehtesham, M, Kabos, P, Kabosova, A, Neuman, T, Black, KL and Yu, JS (2002). The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 62: 5657-5663.
19. Moore, XL, Lu, J, Sun, L, Zhu, CJ, Tan, P and Wong, MC (2004). Endothelial progenitor cells' "homing" specifcity to brain tumors. Gene Ther 11: 811-818.
20. Nakamura, K, Ito, Y, Kawano, Y, Kurozumi, K, Kobune, M, Tsuda, H et al. (2004). Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 11: 1155-1164.
21. Pisati, F, Belicchi, M, Acerbi, F, Marchesi, C, Giussani, C, Gavina, M et al. (2007). Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models. Cancer Res 67: 3054-3063.
22. Tabatabai, G, Bähr, O, Möhle, R, Eyüpoglu, IY, Boehmler, AM, Wischhusen, J et al. (2005). Lessons from the bone marrow: how malignant glioma cells attract adult haematopoietic progenitor cells. Brain 128(Pt 9): 2200-2211.
23. Han, X, Meng, X, Yin, Z, Rogers, A, Zhong, J, Rillema, P et al. (2009). Inhibition of intracranial glioma growth by endometrial regenerative cells. Cell Cycle 8: 606-610.
24. Nakamizo, A, Marini, F, Amano, T, Khan, A, Studeny, M, Gumin, J et al. (2005). Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65: 3307-3318.
25. Miletic, H, Fischer, Y, Litwak, S, Giroglou, T, Waerzeggers, Y, Winkeler, A et al. (2007). Bystander killing of malignant glioma by bone marrow-derived tumor-infltrating progenitor cells expressing a suicide gene. Mol Ther 15: 1373-1381.
26. Bexell, D, Gunnarsson, S, Tormin, A, Darabi, A, Gisselsson, D, Roybon, L et al. (2009). Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther 17: 183-190.
27. Studeny, M, Marini, FC, Champlin, RE, Zompetta, C, Fidler, IJ and Andreeff, M (2002). Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62: 3603-3608.
28. Khakoo, AY, Pati, S, Anderson, SA, Reid, W, Elshal, MF, Rovira, II et al. (2006). Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 203: 1235-1247. (Pubitemid 43736593)
29. Hung, SC, Deng, WP, Yang, WK, Liu, RS, Lee, CC, Su, TC et al. (2005). Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clin Cancer Res 11: 7749-7756.
30. Komarova, S, Kawakami, Y, Stoff-Khalili, MA, Curiel, DT and Pereboeva, L (2006). Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 5: 755-766.
31. Kallifatidis, G, Beckermann, BM, Groth, A, Schubert, M, Apel, A, Khamidjanov, A et al. (2008). Improved lentiviral transduction of human mesenchymal stem cells for therapeutic intervention in pancreatic cancer. Cancer Gene Ther 15: 231-240.
32. Duan, X, Guan, H, Cao, Y and Kleinerman, ES (2009). Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. Cancer 115: 13-22.
33. Xiang, J, Tang, J, Song, C, Yang, Z, Hirst, DG, Zheng, QJ et al. (2009). Mesenchymal stem cells as a gene therapy carrier for treatment of fbrosarcoma. Cytotherapy 11: 516-526.
34. Kidd, S, Spaeth, E, Dembinski, JL, Dietrich, M, Watson, K, Klopp, A et al. (2009). Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 27: 2614-2623.
35. Gao, P, Ding, Q, Wu, Z, Jiang, H and Fang, Z (2010). Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett 290: 157-166.
36. Uchibori, R, Okada, T, Ito, T, Urabe, M, Mizukami, H, Kume, A et al. (2009). Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J Gene Med 11: 373-381.
37. Xin, H, Sun, R, Kanehira, M, Takahata, T, Itoh, J, Mizuguchi, H et al. (2009). Intratracheal delivery of CX3CL1-expressing mesenchymal stem cells to multiple lung tumors. Mol Med 15: 321-327.
38. Gao, J, Dennis, JE, Muzic, RF, Lundberg, M and Caplan, AI (2001). The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs (Print) 169: 12-20.
39. Harting, MT, Jimenez, F, Xue, H, Fischer, UM, Baumgartner, J, Dash, PK et al. (2009). Intravenous mesenchymal stem cell therapy for traumatic brain injury. J Neurosurg 110: 1189-1197.
40. Koponen, JK, Kekarainen, T, E Heinonen, S, Laitinen, A, Nystedt, J, Laine, J et al. (2007). Umbilical cord blood-derived progenitor cells enhance muscle regeneration in mouse hindlimb ischemia model. Mol Ther 15: 2172-2177.
41. Sato, H, Kuwashima, N, Sakaida, T, Hatano, M, Dusak, JE, Fellows-Mayle, WK et al. (2005). Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors. Cancer Gene Ther 12: 757-768.
42. Birnbaum, T, Roider, J, Schankin, CJ, Padovan, CS, Schichor, C, Goldbrunner, R et al. (2007). Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neurooncol 83: 241-247.
43. Schichor, C, Birnbaum, T, Etminan, N, Schnell, O, Grau, S, Miebach, S et al. (2006). Vascular endothelial growth factor A contributes to glioma-induced migration of human marrow stromal cells (hMSC). Exp Neurol 199: 301-310.
44. Aghi, M and Chiocca, EA (2005). Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors. Mol Ther 12: 994-1005.
45. Bababeygy, SR, Cheshier, SH, Hou, LC, Higgins, DM, Weissman, IL and Tse, VC (2008). Hematopoietic stem cell-derived pericytic cells in brain tumor angio-architecture. Stem Cells Dev 17: 11-18.
46. Rajantie, I, Ilmonen, M, Alminaite, A, Ozerdem, U, Alitalo, K and Salven, P (2004). Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 104: 2084-2086.
47. Bergers, G and Benjamin, LE (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410.
48. Bergers, G and Song, S (2005). The role of pericytes in blood-vessel formation and maintenance. Neuro-oncology 7: 452-464.
49. Sasaki, M, Abe, R, Fujita, Y, Ando, S, Inokuma, D and Shimizu, H (2008). Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J Immunol 180: 2581-2587.
50. Wu, Y, Chen, L, Scott, PG and Tredget, EE (2007). Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 25: 2648-2659.
51. Dvorak, HF (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650-1659.
52. Dwyer, RM, Potter-Beirne, SM, Harrington, KA, Lowery, AJ, Hennessy, E, Murphy, JM et al. (2007). Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 13: 5020-5027.
53. Spaeth, E, Klopp, A, Dembinski, J, Andreeff, M and Marini, F (2008). Infammation and tumor microenvironments: defning the migratory itinerary of mesenchymal stem cells. Gene Ther 15: 730-738.
54. Tormin, A, Brune, JC, Olsson, E, Valcich, J, Neuman, U, Olofsson, T et al. (2009). Characterization of bone marrow-derived mesenchymal stromal cells (MSC) based on gene expression profling of functionally defned MSC subsets. Cytotherapy 11: 114-128.
55. Ho, IA, Chan, KY, Ng, WH, Guo, CM, Hui, KM, Cheang, P et al. (2009). Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma. Stem Cells 27: 1366-1375.
56. Maestroni, GJ, Hertens, E and Galli, P (1999). Factor(s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice. Cell Mol Life Sci 55: 663-667.
57. Otsu, K, Das, S, Houser, SD, Quadri, SK, Bhattacharya, S and Bhattacharya, J (2009). Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Blood 113: 4197-4205.
58. Ohlsson, LB, Varas, L, Kjellman, C, Edvardsen, K and Lindvall, M (2003). Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix. Exp Mol Pathol 75: 248-255.
59. Lu, YR, Yuan, Y, Wang, XJ, Wei, LL, Chen, YN, Cong, C et al. (2008). The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther 7: 245-251.
60. Kucerova, L, Altanerova, V, Matuskova, M, Tyciakova, S and Altaner, C (2007). Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res 67: 6304-6313.
61. Coffelt, SB, Marini, FC, Watson, K, Zwezdaryk, KJ, Dembinski, JL, LaMarca, HL et al. (2009). The pro-infammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci USA 106: 3806-3811.
62. Djouad, F, Plence, P, Bony, C, Tropel, P, Apparailly, F, Sany, J et al. (2003). Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102: 3837-3844.
63. Karnoub, AE, Dash, AB, Vo, A P, Sullivan, A, Brooks, MW, Bell, GW et al. (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563.
64. Zhu, W, Xu, W, Jiang, R, Qian, H, Chen, M, Hu, J et al. (2006). Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol 80: 267-274.
65. Spaeth, EL, Dembinski, JL, Sasser, AK, Watson, K, Klopp, A, Hall, B et al. (2009). Mesenchymal stem cell transition to tumor-associated fbroblasts contributes to fbrovascular network expansion and tumor progression. PLoS ONE 4: e4992.
66. Beckermann, BM, Kallifatidis, G, Groth, A, Frommhold, D, Apel, A, Mattern, J et al. (2008). VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer 99: 622-631.
67. Zischek, C, Niess, H, Ischenko, I, Conrad, C, Huss, R, Jauch, KW et al. (2009). Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Ann Surg 250: 747-753.
68. Cavarretta, IT, Altanerova, V, Matuskova, M, Kucerova, L, Culig, Z and Altaner, C (2010). Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol Ther 18: 223-231.
69. Kucerova, L, Matuskova, M, Pastorakova, A, Tyciakova, S, Jakubikova, J, Bohovic, R et al. (2008). Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J Gene Med 10: 1071-1082.
70. Elzaouk, L, Moelling, K and Pavlovic, J (2006). Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp Dermatol 15: 865-874.
71. Hong, X, Miller, C, Savant-Bhonsale, S and Kalkanis, SN (2009). Antitumor treatment using interleukin-12-secreting marrow stromal cells in an invasive glioma model. Neurosurgery 64: 1139-1146; discussion 1146.
72. Xu, G, Jiang, XD, Xu, Y, Zhang, J, Huang, FH, Chen, ZZ et al. (2009). Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats. Cell Biol Int 33: 466-474.
73. Studeny, M, Marini, FC, Dembinski, JL, Zompetta, C, Cabreira-Hansen, M, Bekele, BN et al. (2004). Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96: 1593-1603.
74. Xin, H, Kanehira, M, Mizuguchi, H, Hayakawa, T, Kikuchi, T, Nukiwa, T et al. (2007). Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells 25: 1618-1626. (Pubitemid 47121838)
75. Gunnarsson, S, Bexell, D, Svensson, A, Siesjö, P, Darabi, A and Bengzon, J (2010). Intratumoral IL-7 delivery by mesenchymal stromal cells potentiates IFNgamma-transduced tumor cell immunotherapy of experimental glioma. J Neuroimmunol 218: 140-144.
76. Kim, SM, Lim, JY, Park, SI, Jeong, CH, Oh, JH, Jeong, M et al. (2008). Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 68: 9614-9623.
77. Menon, LG, Kelly, K, Yang, HW, Kim, SK, Black, PM and Carroll, RS (2009). Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 27: 2320-2330.
78. Sasportas, LS, Kasmieh, R, Wakimoto, H, Hingtgen, S, van de Water, JA, Mohapatra, G et al. (2009). Assessment of therapeutic effcacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 106: 4822-4827.
79. Loebinger, MR, Eddaoudi, A, Davies, D and Janes, SM (2009). Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 69: 4134-4142.
80. Yamamoto, M and Curiel, DT (2010). Current issues and future directions of oncolytic adenoviruses. Mol Ther 18: 243-250.
81. Power, AT and Bell, JC (2007). Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther 15: 660-665.
82. Sonabend, AM, Ulasov, IV, Tyler, MA, Rivera, AA, Mathis, JM and Lesniak, MS (2008). Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells 26: 831-841.
83. Yong, RL, Shinojima, N, Fueyo, J, Gumin, J, Vecil, GG, Marini, FC et al. (2009). Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res 69: 8932-8940.
84. Hanahan, D and Folkman, J (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
85. Bergers, G, Song, S, Meyer-Morse, N, Bergsland, E and Hanahan, D (2003). Benefts of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111: 1287-1295.
86. Pietras, A, Gisselsson, D, Ora, I, Noguera, R, Beckman, S, Navarro, S et al. (2008). High levels of HIF-2alpha highlight an immature neural crest-like neuroblastoma cell cohort located in a perivascular niche. J Pathol 214: 482-488.
87. Hamzah, J, Jugold, M, Kiessling, F, Rigby, P, Manzur, M, Marti, HH et al. (2008). Vascular normalization in Rgs5-defcient tumours promotes immune destruction. Nature 453: 410-414.
88. Räty, JK, Liimatainen, T, Unelma Kaikkonen, M, Gröhn, O, Airenne, KJ, Jumani Airenne, K et al. (2007). Non-invasive Imaging in Gene Therapy. Mol Ther 15: 1579-1586.
89. Loebinger, MR, Kyrtatos, PG, Turmaine, M, Price, AN, Pankhurst, Q, Lythgoe, MF et al. (2009). Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles. Cancer Res 69: 8862-8867.
90. Wu, X, Hu, J, Zhou, L, Mao, Y, Yang, B, Gao, L et al. (2008). In vivo tracking of superparamagnetic iron oxide nanoparticle-labeled mesenchymal stem cell tropism to malignant gliomas using magnetic resonance imaging. Laboratory investigation. J Neurosurg 108: 320-329.
91. Zhang, Z, Jiang, Q, Jiang, F, Ding, G, Zhang, R, Wang, L et al. (2004). In vivo magnetic resonance imaging tracks adult neural progenitor cell targeting of brain tumor. Neuroimage 23: 281-287.
92. Anderson, SA, Glod, J, Arbab, AS, Noel, M, Ashari, P, Fine, HA et al. (2005). Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood 105: 420-425.
93. Thu, MS, Najbauer, J, Kendall, SE, Harutyunyan, I, Sangalang, N, Gutova, M et al. (2009). Iron labeling and pre-clinical MRI visualization of therapeutic human neural stem cells in a murine glioma model. PLoS ONE 4: e7218.
94. Wang, H, Cao, F, De, A, Cao, Y, Contag, C, Gambhir, SS et al. (2009). Traffcking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. Stem Cells 27: 1548-1558.
95. Tang, Y, Shah, K, Messerli, SM, Snyder, E, Breakefeld, X and Weissleder, R (2003). In vivo tracking of neural progenitor cell migration to glioblastomas. Hum Gene Ther 14: 1247-1254.
96. Bieback, K, Hecker, A, Kocaömer, A, Lannert, H, Schallmoser, K, Strunk, D et al. (2009). Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 27: 2331-2341.
97. Müller, I, Kordowich, S, Holzwarth, C, Spano, C, Isensee, G, Staiber, A et al. (2006). Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy 8: 437-444.
98. Schallmoser, K, Rohde, E, Reinisch, A, Bartmann, C, Thaler, D, Drexler, C et al. (2008). Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum. Tissue Eng Part C Methods 14: 185-196.
99. Bernardo, ME, Zaffaroni, N, Novara, F, Cometa, AM, Avanzini, MA, Moretta, A et al. (2007). Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 67: 9142-9149.
100. Rubio, D, Garcia-Castro, J, Martín, MC, de la Fuente, R, Cigudosa, JC, Lloyd, AC et al. (2005). Spontaneous human adult stem cell transformation. Cancer Res 65: 3035-3039.
101. Røsland, GV, Svendsen, A, Torsvik, A, Sobala, E, McCormack, E, Immervoll, H et al. (2009). Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res 69: 5331-5339.
102. Mishra, PJ, Mishra, PJ, Humeniuk, R, Medina, DJ, Alexe, G, Mesirov, JP et al. (2008). Carcinoma-associated fbroblast-like differentiation of human mesenchymal stem cells. Cancer Res 68: 4331-4339.
103. Xian, X, Håkansson, J, Ståhlberg, A, Lindblom, P, Betsholtz, C, Gerhardt, H et al. (2006). Pericytes limit tumor cell metastasis. J Clin Invest 116: 642-651.
104. Uccelli, A, Moretta, L and Pistoia, V (2008). Mesenchymal stem cells in health and disease. Nat Rev Immunol 8: 726-736.
105. Najar, M, Rouas, R, Raicevic, G, Boufker, HI, Lewalle, P, Meuleman, N et al. (2009). Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 11: 570-583.
106. Renner, P, Eggenhofer, E, Rosenauer, A, Popp, FC, Steinmann, JF, Slowik, P et al. (2009). Mesenchymal stem cells require a suffcient, ongoing immune response to exert their immunosuppressive function. Transplant Proc 41: 2607-2611.
107. Ren, G, Su, J, Zhang, L, Zhao, X, Ling, W, L'huillie, A et al. (2009). Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 27: 1954-1962.
108. Pawelek, JM and Chakraborty, AK (2008). Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis. Nat Rev Cancer 8: 377-386.
109. Lazennec, G and Jorgensen, C (2008). Concise review: adult multipotent stromal cells and cancer: risk or beneft? Stem Cells 26: 1387-1394.
110. Klopp, AH, Spaeth, EL, Dembinski, JL, Woodward, WA, Munshi, A, Meyn, RE et al. (2007). Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res 67: 11687-11695